Innospec Inc. develops, manufactures, blends, markets, and supplies specialty chemicals in the United States, the rest of North America, the United Kingdom, the rest of Europe, and internationally. The company is headquartered in Englewood, Colorado.
125 articles
Innospec Inc scheduled its Q3 2026 earnings release for November 3, following Q2 revenue growth of 11.8% to USD 491.4 million. Adjusted earnings exceeded consensus estimates, while the stock traded at
Argus Research raised its price target for Innospec Inc. to $103.00, citing its chemicals and fuel additives operations. The stock currently trades at $96.18.
Innospec reported a strong Q2 2026 with 12% revenue growth to $491.4 million, driven by gains across Performance Chemicals, Fuel Specialties, and Oilfield Services. The company maintains a debt-free b
Allspring Global Investments Holdings LLC disclosed a 4.7% passive stake in Innospec Inc., holding 1,161,421 shares with sole voting power as of September 30, 2026.
Allspring Global Investments reduced its beneficial ownership in Innospec Inc. to 4.7% per a recent SEC filing. As of September 30, 2026, the firm holds 1,161,421 shares while maintaining sole voting
Allspring Global Investments Holdings, LLC filed a Schedule 13G with the SEC, revealing a 4.7% beneficial ownership stake in specialty chemical firm Innospec Inc., totaling 1,161,421 shares.
Innospec Inc. Senior VP Ian McRobbie received 3,164 phantom stock shares per Form 4 filing, vesting in stages through October 2028 contingent on continued employment.
Innospec Inc submitted a Form 4 regulatory filing on October 5th, as reported by Investing.com, concerning insider trading activities for the specialty chemical firm.
Innospec Inc. submitted a Form 4 disclosing insider transactions by EVP & CFO Ian Cleminson on October 1, 2026. The filing details a grant of 4,792 phantom stock shares vesting until October 2028.
Innospec Inc.'s Senior Vice President of Human Resources, Louis Hardy Griffin III, acquired 2,685 phantom stock units on October 1, 2026. The units vest through October 2028 contingent on continued em
Innospec Inc shares hit a 52-week high after reporting Q2 earnings of $1.27 per share and revenue of $491.4 million, both exceeding analyst expectations.
Innospec Inc., a global specialty chemicals provider, will report Q3 2026 earnings on November 3, 2026, followed by a conference call on November 4.
Innospec Inc. will release its third-quarter 2026 earnings results on November 3, 2026, followed by a conference call with executives on November 4.
Innospec Inc stock reached a new 52-week high of $100.48 after reporting Q2 2026 revenues of $491.4 million, surpassing analyst expectations with strong adjusted earnings per share.
Avient launched Nymax FR REC flame-retardant recycled polyamide grades containing 42-77% post-industrial recycled content to support electrification and circularity initiatives. Alongside this product
Innospec Inc shares reached a 52-week high of $97.2 following better-than-expected Q2 2026 earnings with adjusted EPS of $1.27 and revenue of $491.4 million.
Innospec Inc reported a strong Q2 2026 earnings beat with adjusted EPS of $1.27 and revenue of $491.4 million, driving its stock near a 52-week high despite decreased operating cash flow.
Innospec Inc stock reached a 52-week high of $97.2 following Q2 2026 results that beat EPS and revenue projections. The company maintains strong financial health and has increased dividends for 12 con
Innospec Inc., a specialty chemicals company, presents an overview of its stock price, financial performance, and analyst ratings. The report details key statistics and operational segments to provide
Innospec Inc. reported Q1 and Q2 2024 earnings, beating EPS estimates but missing revenue targets, with stock trading at $98.11.
Innospec Inc (IOSP) maintains a long-term positive bias despite neutral near-term readings. AI models propose trading strategies including momentum breakouts and risk-hedging with a 26.9:1 risk-reward
Innospec Inc won the Regulatory & Compliance Excellence award at the Cosmetics Business Innovation Awards for its ethical, non-animal testing methods for cosmetic ingredients, potentially influencing
Innospec Inc. shares reached a 52-week high of $95.07 following strong Q2 2026 financial results that surpassed earnings and revenue expectations.
Innospec Inc met Q2 2023 EPS expectations at €1.11 but missed revenue projections by €13.47 million, reporting €415.77 million with 2.74% YoY growth. Next earnings are scheduled for November 10, 2026.
Innospec reported strong first-half 2026 results with increased sales and net income, alongside ongoing share repurchase activities. Analysts suggest the stock may be 6% undervalued following these fi
Innospec Inc. reported strong Q2 2026 earnings and completed a $34.87 million share repurchase program. The company focuses on specialized chemicals earnings despite raw material volatility.
Innospec Inc reported Q1 2024 earnings with an EPS beat of $1.75 against consensus, while revenue of $500.20 million slightly missed expectations. The release includes access to the earnings call and
Innospec Inc. shares reached a 52-week high of $94.67 following strong Q2 2026 financial results that exceeded earnings and revenue expectations despite near-term supply constraints.
Innospec reported Q2 2026 sales of US$491.4 million, achieving a debt-free balance sheet that drove a 7.5% stock rise. While authorizing a US$75 million share repurchase, the company noted risks from
Innospec Inc. released its Q2 2026 earnings call presentation, reporting EPS of $1.27 and revenue of $491.40 million, surpassing analyst estimates.
ChemBrief